Randomized phase 2 study of nab-paclitaxel and gemcitabine with or without tocilizumab as first-line treatment in patients with advanced pancreatic cancer (PACTO)

被引：0
|
作者：
Chen, Inna Markovna
Johansen, Julia S.
Theile, Susann
Madsen, Kasper
Dajani, Olav
Lorentzen, Torben
Zimmers, Teresa
Nielsen, Dorte
机构：
[1] Copenhagen Univ Hosp Herlev & Gentofte, Herlev, Denmark
[2] Oslo Univ Hosp, Oslo, Norway
[3] Indiana Univ Sch Med, Indianapolis, IN USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4147
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Nab-paclitaxel plus S-1 versus nab-paclitaxel plus gemcitabine in patients with advanced pancreatic cancer: a multicenter, randomized, phase II study
    Jin, Min
    Liu, Hong-Li
    Xue, Jun
    Ma, Hong
    Liu, Jun-Li
    Lin, Zhen-Yu
    Wang, Jing
    Bao, Le-Qun
    Luo, Zhi-Guo
    Yu, Xiong-Jie
    Li, Shuang
    Hu, Jian-Li
    Zhang, Tao
    ONCOLOGIST, 2024, 29 (10): : e1406 - e1418
  • [32] Analysis of prognostic factors in advanced pancreatic cancer (APDAC) patients (pts) undergoing to first-line nab-paclitaxel (Nab-P) and gemcitabine (G) treatment
    Giordano, Guido
    Vaccaro, Vanja
    Lucchini, Eleonora
    Bertocchi, Paola
    Bergamo, Francesca
    Musettini, Gianna
    Santoni, Matteo
    Lo Re, Giovanni
    Giommoni, Elisa
    Russano, Marco
    Campidoglio, Serena
    Santini, Daniele
    Vasile, Enrico
    Cascinu, Stefano
    Zagonel, Vittorina
    Zaniboni, Alberto
    Melisi, Davide
    Milella, Michele
    Febbraro, Antonio
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (03)
  • [33] Gemcitabine plus nab-paclitaxel followed by maintenance treatment with gemcitabine alone as first-line treatment for older adults with locally advanced or metastatic pancreatic cancer
    Petrioli, Roberto
    Torre, Pamela
    Pesola, Guido
    Paganini, Giovanni
    Paolelli, Loretta
    Miano, Salvatora Tindara
    Martellucci, Ignazio
    Francini, Guido
    Francini, Edoardo
    JOURNAL OF GERIATRIC ONCOLOGY, 2020, 11 (04) : 647 - 651
  • [34] First-Line Gemcitabine and Nab-Paclitaxel Chemotherapy for Localized Pancreatic Ductal Adenocarcinoma
    Pat Gulhati
    Laura Prakash
    Matthew H. G. Katz
    Xuemei Wang
    Milind Javle
    Rachna Shroff
    David Fogelman
    Jeffrey E. Lee
    Ching-Wei D. Tzeng
    Jeffrey H. Lee
    Brian Weston
    Eric Tamm
    Priya Bhosale
    Eugene J. Koay
    Anirban Maitra
    Huamin Wang
    Robert A. Wolff
    Gauri R. Varadhachary
    Annals of Surgical Oncology, 2019, 26 : 619 - 627
  • [35] First-Line Gemcitabine and Nab-Paclitaxel Chemotherapy for Localized Pancreatic Ductal Adenocarcinoma
    Gulhati, Pat
    Prakash, Laura
    Katz, Matthew H. G.
    Wang, Xuemei
    Javle, Milind
    Shroff, Rachna
    Fogelman, David
    Lee, Jeffrey E.
    Tzeng, Ching-Wei D.
    Lee, Jeffrey H.
    Weston, Brian
    Tamm, Eric
    Bhosale, Priya
    Koay, Eugene J.
    Maitra, Anirban
    Wang, Huamin
    Wolff, Robert A.
    Varadhachary, Gauri R.
    ANNALS OF SURGICAL ONCOLOGY, 2019, 26 (02) : 619 - 627
  • [36] Nab-paclitaxel and gemcitabine for the treatment of patients with metastatic pancreatic cancer
    Borazanci, Erkut
    Von Hoff, Daniel D.
    EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY, 2014, 8 (07) : 739 - 747
  • [37] FOLFIRINOX versus gemcitabine plus nab-paclitaxel as the first-line chemotherapy in metastatic pancreatic cancer
    Ay, Seval
    Atci, Muhammed Mustafa
    Arikan, Rukiye
    Dulgar, Ozgecan
    Ozyukseler, Deniz Tataroglu
    Paksoy, Nail
    Dogan, Izzet
    Oztosun, Bugra
    Tastekin, Didem
    Oven, Basak Bala
    Gumus, Mahmut
    JOURNAL OF CHEMOTHERAPY, 2022, 34 (07) : 465 - 471
  • [38] Pancreatic enzyme replacement therapy improves survival in patients receiving nab-paclitaxel plus gemcitabine as first-line treatment for advanced pancreatic adenocarcinoma
    Lavacchi, D.
    Winchler, C.
    Giommoni, E.
    Vascotto, I. A.
    Romano, S.
    Scolari, F.
    Taddei, A.
    Pillozzi, S.
    Galli, A.
    Antonuzzo, L.
    ANNALS OF ONCOLOGY, 2023, 34 : S920 - S920
  • [39] Combination nab-paclitaxel (Nab-P) plus gemcitabine (G) as first-line treatment in advanced pancreatic cancer (APC): Our experience.
    De Vita, Fernando
    Orditura, Michele
    Febbraro, Antonio
    Morgillo, Floriana
    Laterza, Maria Maddalena
    Fabozzl, Alesslo
    Giordano, Guido
    Savastano, Beatrice
    Petrillo, Angelica
    Ventriglia, Joie
    Ciardiello, Fortunato
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [40] First-line gemcitabine plus nab-paclitaxel for elderly patients with metastatic pancreatic cancer: Crossing the frontier of age?
    Vivaldi, Caterina
    Salani, Francesca
    Rovesti, Giulia
    Pecora, Irene
    Catanese, Silvia
    Casadei-Gardini, Andrea
    Massa, Valentina
    Bernardini, Laura
    Riggi, Laura
    Andrikou, Kalliopi
    Rapposelli, Giovanni I.
    Formica, Vincenzo
    Lencioni, Monica
    Falcone, Alfredo
    Vasile, Enrico
    Fornaro, Lorenzo
    EUROPEAN JOURNAL OF CANCER, 2020, 137 : 108 - 116
12345